|
 |
| home > epc > spring 2003 > the changing face of diagnostics and its impact on the pharmaceutical industry - an update |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
The diagnostic sector, at least as defined for the in vitro diagnostics (IVD) business, is little brother to the pharma industry. The markets are globally distributed in a very similar fashion but the 2002 IVD market was only valued at just over 20 billion dollars (US$24.1 billion) with global growth of less than five per cent per annum (4.3%). This is in great contrast to the pharma market valued at almost 400 billion (US$395 billion) and achieving growth of above 10 per cent per annum (12 per cent). The global distributions are compared in Figure 1 .
Three years ago in this publication the possible impact of diagnostics on the pharma industry was examined, a strong driving force at that time being the reduced growth of the IVD market. The need to identify new areas for growth in diagnostics was linked to the belief that tests that could define those patients most likely to respond to specific drugs or classes of drugs as therapeutics: theranostics.
The pharma industry has, over several decades, resisted the use of diagnostic testing for the selection of therapeutics. The potential for loss of drug sales through better selection of drugs of choice or even the non-selection of particular therapeutics was not considered economically sound. The major change over the last three years has been in the technological developments that have created at least "the start of the beginning" of personalised medicine.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Biovian expands - and invests in new capacity
More info >> |
|
 |
